Related Experiment Video
Updated: Jun 13, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.5K
ELABELA-32 Alleviates Doxorubicin-Induced Chronic Cardiotoxicity by Inhibiting the TGF-β/Smad Signaling Pathway
Shuang Zhou1, Zhuo Meng2, Lin Lu1
1Department of Intensive Care Unit, Xiamen Cardiovascular Hospital, Xiamen University, No. 2999, Jinshan Road, Huli District, Xiamen, Fujian, China.
Cardiovascular Toxicology
|May 19, 2025
Summary
ELABELA (ELA)-32 peptide protects against doxorubicin-induced heart damage by reducing oxidative stress and fibrosis. This peptide therapy shows potential for preventing chemotherapy-related cardiotoxicity.
Area of Science:
- Cardiology
- Pharmacology
- Molecular Biology
Background:
- Doxorubicin (DOX) chemotherapy can cause significant cardiotoxicity, characterized by cardiac fibrosis, oxidative stress, and cardiomyocyte apoptosis.
- ELABELA (ELA), an endogenous ligand for the apelin receptor (APJ/APLNR), plays a role in cardiovascular regulation.
- The specific protective mechanisms of ELA-32 against DOX-induced cardiotoxicity require further elucidation.
Purpose of the Study:
- To investigate the cardioprotective effects of ELA-32 against doxorubicin-induced cardiotoxicity.
- To elucidate the underlying molecular mechanisms, particularly the involvement of the TGF-β/Smad signaling pathway.
Main Methods:
- A mouse model of chronic doxorubicin cardiotoxicity was established (20 mg/kg cumulative dose).
- Exogenous ELA-32 was administered via microinjection pump to assess its effects on cardiac function, oxidative stress, and fibrosis.
- In vitro studies utilized rat cardiomyocytes (H9C2 cells) to evaluate ELA-32's protection against DOX-induced cytotoxicity.
- The role of the TGF-β/Smad pathway was assessed by activating it with TGF-β1.
Main Results:
- ELA-32 administration significantly improved cardiac function and survival in mice subjected to chronic DOX treatment.
- Exogenous ELA-32 reduced oxidative stress markers and myocardial fibrosis in the DOX-induced cardiotoxicity model.
- In vitro, ELA-32 pretreatment protected H9C2 cells from DOX-induced cytotoxicity.
- The cardioprotective effects of ELA-32 were abolished upon activation of the TGF-β/Smad signaling pathway.
Conclusions:
- ELA-32 demonstrates significant cardioprotective effects against chronic doxorubicin-induced cardiotoxicity.
- The mechanism involves the modulation of the TGF-β/Smad signaling pathway, attenuating cardiac fibrosis.
- ELA-32 holds promise as a therapeutic agent for preventing or treating doxorubicin-related cardiotoxicity.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:22Heart Failure Drugs: β-Blockers
321
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
321